Organisation paid for research Program year 2025 Source: CMS Open Payments

Clinnova Research Solutions

Neither a doctor nor a teaching hospital

Research payments

$988,957

572 payments

Through program year 2025, Clinnova Research Solutions is reported as receiving $988,957 in research payments, across 572 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $135,029 49
2024 Research $239,906 48
2023 Research $181,160 140
2022 Research $432,862 335

Breakdown

Who paid Research payments · program years 2022–2025
  1. AstraZeneca Pharmaceuticals LP $245,153 8 payments
  2. Novartis Pharmaceuticals Corporation $229,774 6 payments
  3. Regeneron Pharmaceuticals, Inc. $191,531 423 payments
  4. Bausch Health US, LLC $104,729 33 payments
  5. Celgene Corporation $58,323 5 payments
  6. AbbVie, Inc. $58,050 11 payments
  7. Pfizer Inc. $37,443 6 payments
  8. Teva Pharmaceuticals USA, Inc. $32,197 55 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $15,800 19 payments
  10. F. Hoffmann-La Roche AG $11,808 4 payments
Studies the money was for Research payments · program years 2022–2025
  1. Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) $189,508 420 payments
  2. A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fibrosis Who Are Carriers of the PNPLA3 rs738409 148M Risk Allele $172,538 3 payments
  3. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Ensovibep (Mp0420) in Ambulatory Adult Patients With Symptomatic Covid-19 $124,148 4 payments
  4. A Randomized, Controlled, Multicenter, Open-Label Trial Comparing A Post-Discharge Care Pathway Involving Aggressive LDL-C Management With Inclisiran With Usual Care in Patients With A Recent Acute Coronary Syndrome $105,626 2 payments
  5. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis $104,729 33 payments
  6. COSMOS - A Phase IIa Randomized Double-blind Placebo-controlled Study to Evaluate the Safety Tolerability and Pharmacodynamics of AZD4831 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fibrosis $72,616 5 payments
  7. A Phase 1 Openlabel Nonrandomized Study to Investigate the Safety and PK Following Multiple Oral Doses of Pf07321332 Nirmatrelvirritonavir in Adult Participants With Covid19 and Severe Renal Impairment Either on Hemodialysis Or Not on Hemodialysis $37,443 6 payments
  8. A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease $33,185 6 payments
  9. Tv50717-Cns-40223 $32,197 55 payments
  10. PhIII Yellowstone Induction Study # 1 OZANIMOD in Moderate to Severe CD (RPC01-3201) $23,742 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record